Hematology Reports最新文献

{"title":"Anemia of Chronic Disease: Pathophysiology, Diagnosis and Management.","authors":"Keziah Abbotts, Priya Sriskandarajah","doi":"10.3390/hematolrep18040048","DOIUrl":"10.3390/hematolrep18040048","url":null,"abstract":"<p><p>Anemia of chronic disease (ACD) is a condition linked to chronic immune activation secondary to a wide range of infectious, inflammatory, and autoimmune diseases. It is characterized by a state of iron-restricted erythropoiesis, in which prolonged activation of cytokines leads to retention of iron within the reticulo-endothelial system, driven primarily by hepcidin. Reduced iron availability contributes to a blunted response by erythropoietin and impaired erythropoiesis, in addition to a shortened red cell lifespan. In patients found to have anemia and evidence of chronic inflammation, parameters such as mean cell volume, iron studies, percentage of hypochromic red cells, reticulocyte hemoglobin content, and levels of ferritin, serum transferrin receptor, hepcidin, erythropoietin, and GDF15 are all used to build a picture of anemia of chronic disease. Following this, management normally utilizes erythropoietin-stimulating agents alongside parenteral iron supplementation when treatment of the underlying cause is not available. Newer therapies, such as hypoxia-inducible factor prolyl hydroxylase inhibitors and hepcidin inhibitors, also play a role, while cytokine targets, carbon dots, androgens, and other therapies are emerging as possible treatment routes. Despite its high prevalence, there remain few standardized methods of diagnosis or management in anemia of chronic disease. This narrative review explores long-standing and emerging practices in the diagnosis and management of this condition to ensure an up-to-date understanding.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13397923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pernicious Anemia: Basic Pathophysiology and Diagnostic Challenges in Neuropsychiatric Patients.","authors":"Yin Mon Myat, Kyaw Zin Thein, Thein Hlaing Oo","doi":"10.3390/hematolrep18040047","DOIUrl":"10.3390/hematolrep18040047","url":null,"abstract":"<p><p>Pernicious anemia (PA) represents a significant diagnostic challenge in neuropsychiatric patients due to its subtle and variable presentation. While PA is traditionally associated with clinical and biochemical manifestations of anemia, many patients, particularly those with neuropsychiatric symptoms, may have normal hematologic parameters, delaying recognition and appropriate treatment. Neurological and psychiatric symptoms, ranging from cognitive impairment and mood disorders to subacute combined degeneration (SCD) of the spinal cord, can precede hematologic abnormalities, leading to misdiagnosis or inappropriate management. The lack of a definitive gold standard test for cobalamin deficiency (CD) further complicates identification. Commonly used biomarkers, such as serum cobalamin, methylmalonic acid (MMA), homocysteine (Hcy), intrinsic factor antibodies (IFAs), and parietal cell antibodies (PCAs), each have limitations in diagnosing PA, especially in the absence of overt anemia. The variability in diagnostic criteria and cutoff values across studies adds to the challenge of achieving early and accurate diagnosis. This article reviews the complexities of diagnosing PA in neuropsychiatric patients, evaluates the limitations of current diagnostic methods, and emphasizes the need for a more comprehensive, standardized approach to early detection and treatment. Combining clinical awareness with improved biomarker interpretation is essential for preventing irreversible neurological damage and improving patient outcomes. Improved diagnostic protocols and further research are essential to optimize detection and minimize the risk of long-term neurological damage.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13397824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Scoring System for the Assessment of Quality of Care in the Management of Transfusion Dependent Thalassemia.","authors":"Michael Angastiniotis, Lily Cannon, Androulla Eleftheriou","doi":"10.3390/hematolrep18040046","DOIUrl":"10.3390/hematolrep18040046","url":null,"abstract":"<p><p><b>Objective</b>: To identify criteria which can be used locally to assess the quality of care for thalassaemia patients, leading to quality improvement measures. In low-resource settings, there is often minimal support for services, and the investigations used in patient monitoring are very basic. In order to select standards which can serve quality assessment, consideration is given to what is available in most centres. Importance is given to the need for the local service provider to self-assess the quality of care according to evidence-based minimal standards. <b>Methods</b>: A search in the recent literature was performed to identify measures of quality care in thalassaemia, selecting those which can be used in resource-poor settings. They are then compared to the standards listed in internationally accepted guidelines. <b>Results:</b> Twelve criteria were selected based on the routine information recorded by most centres. These include the following: clinical criteria: mean age (excluding paediatric clinics), pre-transfusion Hb < 9 g/dL, serum ferritin, MRI availability, heart iron (where available) >20 ms, LIC (where available) <3 mg/kg dw, LIC > 15 mg/kg dw, combination chelation within the last year, and BMI < 18.5 kg/m². Social criteria (for adults): completed tertiary education, married/cohabiting, and employed full or part-time. Each is assigned a score with a total range from 0 to 10. <b>Conclusions</b>: Annual scoring according to achievements allows service providers to compare with previous years and conclude which of the basic services need to be further upgraded to achieve quality improvement. Scoring also allows for comparison with standards published in international guidelines. The clear aim is to aim for higher scores each year, indicating better patient outcomes.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13398067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Point-of-Care Hemoglobin Measurements in an Elderly Population with Hematological Disorders and Anemia.","authors":"Ittai Appel, Liat Dizengoff, Nili Stein, Regina Draliuk, Alla Kravits, Shoshan Perek, Amir Warwar, Ibrahim Zoubi, Marwa Naamneh, Adi Kibari, Mouna Ballan-Haj, Olga Valkovsky, Elena Mishchenko, Meir Preis","doi":"10.3390/hematolrep18040045","DOIUrl":"10.3390/hematolrep18040045","url":null,"abstract":"<p><p><b>Background:</b> Patients with severe chronic anemia often require frequent blood transfusions. Many are elderly with comorbidities and limited mobility, making regular hospital visits burdensome. In some cases, patients may receive transfusions despite hemoglobin levels being above the clinical threshold due to logistical challenges, leading to unnecessary exposure to risks, inefficient use of blood units, and resource strain. This study aims to evaluate the use of point-of-care (POC) hemoglobin measurements under controlled outpatient clinic conditions, as an initial step toward potential future home-based monitoring by the patients or their caregivers, with the goal of optimizing transfusion timing, aiming to reduce unnecessary hospital visits while maintaining patient safety. <b>Methods:</b> A total of 127 patients from a hemato-oncology outpatient clinic at Carmel Medical Center were evaluated using a nurse-operated POC device to sample capillary blood, with 236 paired measurements concurrently analyzed via venous blood in the laboratory. Demographic and clinical data were assessed to evaluate factors associated with agreement between POC and laboratory measurements. Statistical analysis included Bland-Altman plots and Pearson correlation coefficients. <b>Results:</b> The POC device showed a moderate correlation with laboratory results (r = 0.73, <i>p</i> < 0.001), with a mean difference of 1.20 g/dL (SD = 1.94 g/dL) but wide limits of agreement (-3.20 to 5.50 g/dL). No significant differences were observed across demographic or clinical subgroups. Notably, all 156 paired measurements with POC-measured hemoglobin >7 g/dL were confirmed by laboratory testing. <b>Conclusions:</b> Although POC hemoglobin devices are not suitable as standalone tools for routine monitoring of chronic anemia, the high negative predictive value observed at the 7 g/dL threshold suggests that they may be useful for ruling out severe anemia. If validated in larger multicenter and home-use studies, POC Hb devices might contribute to reducing unnecessary hospital visits and transfusions.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13398108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Autologous Haematopoietic Transplantation in Leukaemias: When to Consider It in 2026.","authors":"Miklós Udvardy, Lajos Gergely, Róbert Szász, Gyula Reményi, László Imre Pinczés, Árpád Illés","doi":"10.3390/hematolrep18040044","DOIUrl":"10.3390/hematolrep18040044","url":null,"abstract":"<p><p><b>Background:</b> This review aims to provide a comprehensive and practical overview of the evolving role of autologous transplantation in leukaemias, a strategy that was once largely abandoned but has recently regained interest in selected clinical settings. <b>Methods:</b> We reviewed the historical development of autologous transplantation in acute leukaemias, including the early period during which autologous transplantation was considered inferior to allogeneic approaches because of limited graft purification techniques and the inability to induce effective graft-versus-leukaemia (GVL)-like immune responses. We further summarise more recent experimental strategies aimed at improving stem cell purification and enhancing anti-leukaemic immune activity in autologous settings. In addition, we discuss how advances in measurable residual disease (MRD) assessment and molecular risk stratification have contributed to the renewed interest in autologous transplantation in selected subgroups of leukaemia patients. <b>Results:</b> This review identifies clinical situations in which autologous transplantation remains an important therapeutic option, including plasma cell leukaemia, where it continues to represent a standard first-line approach. We also discuss well-defined patient subgroups, particularly selected AML subtypes with intermediate-risk molecular profiles and acute promyelocytic leukaemia (APL) in second remission, in which outcomes following autologous transplantation may be comparable to, or occasionally superior to, those achieved with allogeneic transplantation. In contrast, autologous transplantation currently plays only a limited role in diseases such as chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML). Although attempts to induce potent anti-leukaemic immune effects in autologous settings have so far shown limited clinical efficacy, several emerging strategies appear promising and may further expand the role of autologous transplantation, particularly in elderly or frail patients. <b>Discussion:</b> Overall, current molecular and MRD-based risk stratification strategies, together with emerging immunological and graft-manipulation approaches, may redefine the role of autologous transplantation as a personalised therapeutic option in selected subgroups of leukaemia patients.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13398228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies.","authors":"Jerry Qi, Daniel Park, Nidhi Kejriwal, Austin Yang, Kareem Latif, Sarkis Dagley, Mojtaba Akhtari","doi":"10.3390/hematolrep18040043","DOIUrl":"10.3390/hematolrep18040043","url":null,"abstract":"<p><strong>Background/objectives: </strong>Lisocabtagene maraleucel (liso-cel) is a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). However, most published meta-analyses of CAR-T therapy in LBCL pool data across products, limiting product-specific interpretation.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of clinical trials and retrospective real-world studies evaluating liso-cel monotherapy in R/R LBCL. The primary endpoint was the overall response rate (ORR). Secondary endpoints included complete response (CR), incidence of grade ≥ 3 adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), overall mortality rate (OMR), disease progression-related mortality, and adverse event-related mortality. Pooled proportions were estimated using random-effects models.</p><p><strong>Results: </strong>Eleven studies including 1206 patients were analyzed, comprising five clinical trials and six real-world retrospective cohorts. The pooled ORR was 78%, and the pooled CR rate was 60%. The pooled OMR was 38%, with a disease progression-related mortality of 28% and an adverse event-related mortality of 4%. Severe (grade ≥ 3) CRS and ICANS occurred in 2% and 8%, respectively. Severe (grade ≥ 3) hematologic toxicities were frequent, particularly neutropenia, thrombocytopenia, and anemia.</p><p><strong>Conclusions: </strong>Liso-cel monotherapy demonstrated high pooled response rates and low pooled incidences of severe CRS and ICANS across clinical trials and real-world settings in R/R LBCL. Severe ICANS, although uncommon, remains clinically meaningful, and severe hematologic toxicities were frequent and warrant careful monitoring and supportive care. These findings provide product-specific benchmarks for liso-cel in R/R LBCL.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13397927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Global Gap in the Hemophilia Paradigm Shift: Disparities in Research, Care, and Musculoskeletal Health.","authors":"Felipe Querol-Giner, Magdalena Querol-Giner, Ana Chimeno-Hernández, Pilar Alberola-Zorrilla, Sofía Pérez-Alenda, Santiago Bonanad, Felipe Querol-Fuentes","doi":"10.3390/hematolrep18030042","DOIUrl":"10.3390/hematolrep18030042","url":null,"abstract":"<p><p><b>Background:</b> Hemophilia care has undergone a major therapeutic transformation with the introduction of extended half-life products, non-replacement therapies, and gene therapy. However, the benefits of these advances are not equally distributed worldwide, and their impact on long-term musculoskeletal outcomes remains uncertain. <b>Objective:</b> To analyze global disparities in hemophilia care and research production in the context of recent therapeutic advances, with particular attention to musculoskeletal management, physiotherapy, and scalable strategies for resource-limited settings. <b>Methods:</b> A narrative review with a structured literature search was conducted. Two conceptual blocks were explored: global disparities and access to care in hemophilia, and recent therapeutic advances, including non-replacement therapies, extended half-life products, and gene therapy. Retrieved records were screened using Rayyan, and a structured workflow diagram was used to summarize the literature identification and selection process. A descriptive analysis was also performed to identify representative authors, institutions, and geographic patterns in hemophilia research. <b>Results:</b> The evidence shows substantial global disparities in diagnosis, access to treatment, healthcare infrastructure, and research production. Scientific output remains concentrated in high-income countries, while low- and middle-income regions are underrepresented. Advanced therapies consistently reduce bleeding rates and treatment burden, but concerns remain regarding access, affordability, durability, breakthrough bleeding, and long-term structural joint outcomes. Musculoskeletal complications, including subclinical bleeding and hemophilic arthropathy, remain clinically relevant despite improved hematologic control. <b>Conclusions:</b> The current paradigm shift in hemophilia care is not uniformly experienced worldwide. Addressing global disparities requires not only expanding access to advanced therapies, but also strengthening research capacity, implementing multidisciplinary care models, and integrating scalable interventions such as physiotherapy, patient education, and simplified diagnostic tools. Accessible musculoskeletal assessment strategies may help improve early detection, functional outcomes, and equity of care in resource-limited settings.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 3","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13300408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma.","authors":"Tine Rosenberg, Jannie Kirkegaard, Michael Tveden Gundesen, Anne Mette Ølholm, Karin Brochstedt Dieperink, Thomas Lund","doi":"10.3390/hematolrep18030041","DOIUrl":"10.3390/hematolrep18030041","url":null,"abstract":"<p><p><b>Objectives:</b> For patients with multiple myeloma (MM), an increasing proportion of treatment is now delivered at home. While this shift offers convenience and supports continuity of care, it also demands new ways to ensure patient safety outside the hospital. Although patients receiving home-based treatment are generally clinically stable, each administration still requires a pre-treatment safety assessment, traditionally performed by telephone. We aimed to evaluate whether digital patient-reported outcomes (PROs) could replace these calls to determine treatment readiness. <b>Methods:</b> This feasibility study included 30 patients (median age 76 years, 60% male). Prior to each scheduled treatment, patients completed a digital symptom questionnaire. An algorithm stratified patients according to treatment readiness. In total, 233 questionnaires were distributed and 179 completed (completion rate 77%). Healthcare professionals were blinded to PRO data during the study, and PRO-based assessments were compared with standard nurse-led telephone evaluations after study completion. <b>Results:</b> Digital PRO data reliably identified patients ready for treatment. The algorithm achieved a positive predictive value of 100%, indicating concordance between PRO-based readiness classification and clinical decisions. The negative predictive value was 19%, reflecting that most patients reporting symptoms were ultimately eligible for treatment. Overall, nearly 80% of routine pre-treatment telephone calls could safely be omitted without compromising patient safety. <b>Conclusions:</b> This study suggests that digital PRO-based symptom reporting may support a reduction in routine pre-treatment telephone assessments for selected patients with MM receiving daratumumab. The approach showed potential for streamlining clinical workflows while maintaining patient safety, although confirmatory studies are needed before implementation.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 3","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13300438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eltrombopag for Chemotherapy-Induced Thrombocytopenia: A Multicenter Retrospective Real-World Study.","authors":"Mehmet Baysal, Fatos Dilan Köseoğlu, Sevil Sadri, Ünal Ataş, Ufuk Demirci, Rafiye Çiftçiler, Seval Akpınar, Elif Gülsüm Ümit","doi":"10.3390/hematolrep18030039","DOIUrl":"10.3390/hematolrep18030039","url":null,"abstract":"<p><p><b>Introduction:</b> Chemotherapy-induced thrombocytopenia (CIT) is a common dose-limiting toxicity that disrupts on-time, full-dose chemotherapy, yet no pharmacologic therapy is formally approved. Growing evidence from randomized and late-phase studies with thrombopoietin receptor agonists (TPO-RAs) has renewed interest in targeted supportive care. We evaluated the effectiveness and safety of eltrombopag for CIT in routine clinical practice. <b>Methods</b>: We conducted a small, retrospective, single-arm multicenter cohort study of 31 adults with solid tumors (74.2% stage IV). Given the descriptive, hypothesis-generating nature of this study, no causal inference regarding efficacy can be drawn. Platelet counts and chemotherapy continuity were tracked from baseline through week 12 after eltrombopag initiation. Bleeding, thrombosis, and laboratory safety signals were recorded. <b>Results</b>: The median platelet count increased from 33 × 10⁹/L at baseline to 71 × 10⁹/L at week 1 and 99.5 × 10⁹/L by week 12. Overall, 18/31 patients (58.1%) resumed chemotherapy within 3 weeks, and 15/31 (48.4%) completed planned regimens by week 6. Adverse events were limited to mild, transient elevations in transaminases (<i>n</i> = 3); no major bleeding or thrombotic events occurred. <b>Conclusions</b>: In this real-world multicenter cohort, eltrombopag was associated with rapid platelet recovery and improved chemotherapy deliverability with an acceptable safety profile. The retrospective, single-arm design and the hypothesis-generating nature of these findings preclude definitive conclusions regarding causal efficacy. These observational data highlight the need for prospective controlled trials to characterize the clinical role, optimal dosing, and long-term safety of oral TPO-RAs in CIT.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 3","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13299753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in CAR-T Cell Therapy.","authors":"Caterina Alati, Martina Pitea, Gaetana Porto, Giorgia Policastro, Erica Bilardi, Giovanna Utano, Laura Giordano, Annalisa Sgarlata, Ilaria Maria Delfino, Aurora Idato, Giulia Santoro, Filippo Antonio Canale, Virginia Naso, Massimo Martino","doi":"10.3390/hematolrep18030040","DOIUrl":"10.3390/hematolrep18030040","url":null,"abstract":"<p><p><b>Background</b>: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, achieving high response rates in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. While the efficacy of CAR-T therapy is well established, quality of life (QoL) metrics have become increasingly important for guiding treatment decisions, patient counseling, and survivorship planning. <b>Objectives</b>: Most patients undergoing CAR-T therapy recover their initial QoL within 3 months, an improvement not typically seen with other treatment options. A comprehensive understanding of QoL is essential for delivering patient-centered care in the evolving CAR-T landscape. <b>Conclusions</b>: This review synthesizes current evidence on QoL outcomes in CAR-T recipients, including acute effects, recovery trajectories, comparisons with conventional therapies, and strategies to optimize QoL.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"18 3","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13299569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}